Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head

Banc de Sang i Teixits

Status and phase: Completed; Phase 2; Phase 1

Conditions: Avascular Necrosis of Femur Head

Treatments: Procedure: Standard treatment; Biological: XCEL-MT-OSTEO-ALPHA

Study type: Interventional

Funder types: Other

Identifiers

NCT01605383

2010-023998-18 (EudraCT Number)

XCEL-MT-10-01

Details and patient eligibility

About

The present study evaluates the effect of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head in comparison to the standard treatment of isolated core decompression.

XCEL-MT-OSTEO-ALPHA is a tissue engineering product composed by "ex-vivo" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue.

The working hypothesis proposes that the tissue engineering is a valid and useful technique to achieve bone regeneration, avoiding the progression to collapse of the femoral head.

Full description

Prospective, open-label with blinded assessor, randomized, parallel, single-dose phase I-II clinical trial in which 24 patients affected with osteonecrosis of the femoral head ARCO grade I or II will enter the trial with the primary objective of assessing the feasibility and safety of "ex-vivo" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in osteonecrosis of the femoral head. Secondary objectives are to assess the efficacy of the implantation by imaging (magnetic resonance imaging) and clinical questionnaires (pain by visual analogue scale, quality of life by SF-36 and WOMAC Index).

Patients will be randomized to one of the two treatment arms (core decompression and the tissue engineering product composed by "ex-vivo" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue or the standard treatment of isolated core decompression). Thereafter, patients will be followed for 12 months.

Enrollment: 23 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 to 50 years of age (male and female)
• Osteonecrosis of the hip ARCO grade I or II
• Abscence of systemic or local infection
• Laboratory tests with no relevant abnormal findings that contraindicate the surgery.
• Informed Consent Form signed
• The patient is able to understand the nature of the study

Exclusion criteria

• Osteonecrosis of the hip secondary to femoral neck fracture
• Patients with no closed cartilage
• Surgical implants in the femoral head
• Septic arthritis
• Patients with severe renal insufficiency
• Patients expecting or with liver transplantation
• Positive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg), Hepatitis C (Anti-HCV-Ab) or Syphilis.
• Pregnant woman or intended to become pregnant, or breath feeding
• Neoplasia within the previous 5 years, or without remission
• Immunosuppressive states
• The patient is legally dependent
• Participation in another clinical trial or treated with an investigational medicinal product the previous 30 days
• Cardiac pacemaker, allergy to contrast or any other condition that contraindicates the MRI with contrast agents
• Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria
• The patient does not accept to be followed-up for a period thar could exceed the clinical trial length

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

23 participants in 2 patient groups

XCEL-MT-OSTEO-ALPHA

Experimental group

Description:

"ex-vivo" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head

Treatment:

Biological: XCEL-MT-OSTEO-ALPHA

Standard Treatment

Sham Comparator group

Description:

Isolated core decompression

Treatment:

Procedure: Standard treatment